A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells
- 156 Downloads
The isocoumarin NM-3 reverses resistance of human multiple myeloma (MM) cells to dexamethasone and is in clinical trials. In the present work, the NM-3 analog, 185322, has been studied for activity against MM cells.
Human U266, RPMI8226 and primary MM cells were analyzed for the effects of 185322 on cell cycle distribution, tubulin polymerization and induction of apoptosis.
We show that, in contrast to NM-3, treatment with 185322 is associated with a marked arrest of MM cells in M phase. The results also demonstrate that treatment with 185322 is associated with a rapid decrease in tubulin assembly and an increase in Bcl-2 phosphorylation, consistent with disruption of mitosis. Our results further demonstrate that mitotic failure induced by 185322 results in activation of an apoptotic response in MM cell lines and primary MM cells. By contrast, 185322 had little if any effect on growth and survival of human carcinoma cells.
These findings identify a novel inhibitor of microtubule assembly that induces mitotic arrest and apoptosis of MM cells.
KeywordsIsocoumarins NM-3 analog Multiple myeloma Mitotic arrest Apoptosis
This work was supported by Grants CA100707 and CA42802 awarded by the National Cancer Institute. Mr. Kamal Chauhan is acknowledged for excellent technical support.
- 1.Soulie P, Gamelin E, Eder J (2003) A dose finding study of an oral antiangiogenesis inhibitor, NM-3 safety profile and effects on surrogate markers with once-daily dosing. Abstract No. 777. Proc Amer Soc Clin OncolGoogle Scholar
- 2.Bonate P, Eder J, Soulie P (2003) Pharmacokinetics of a new antiangiogenic isocoumarin derivative, NM-3 in two oral once a day-dose schedules with escalating doses, Abstract No. 537. Proc Amer Soc Clin Oncol 22:132Google Scholar
- 5.Agata N, Tsuchiya A, Issihiki K (2001) NM-3, a novel orally bioavilable antiangeiogenic agents suppresses hypoxia-induced vascular endothelial growth factor (VEGF) in human fibroblasts and tumor cells. Proc AACR 41:587Google Scholar
- 11.Nguyen L, Guyon-Gellin Y, Phan H et al (2004) Design and synthesis of novel NM-3 antiangigenic analogues with increased potency and reduced protein binding. AACR 45:4087Google Scholar